Tofacitinib's Effects on Joint Inflammation and Gut Microbiota in Psoriatic Arthritis
Author Information
Author(s): Picchianti Diamanti Andrea, Panebianco Concetta, Di Gioia Valeria, Bellofatto Ilaria Anna, Salemi Simonetta, Di Rosa Roberta, Sesti Giorgio, Nalli Gabriele, Salerno Gerardo, Finocchiaro Etta, Laganà Bruno
Primary Institution: S. Andrea University Hospital, “Sapienza” University of Rome
Hypothesis
Tofacitinib treatment will reduce joint inflammation and alter gut microbiota composition in bio-naïve psoriatic arthritis patients.
Conclusion
Tofacitinib is effective and safe for treating psoriatic arthritis, leading to significant improvements in disease activity and changes in gut microbiota composition.
Supporting Evidence
- Patients showed significant improvement in clinical scores after 12 months of treatment.
- Ultrasonography confirmed a significant reduction in synovitis scores.
- Tofacitinib treatment was associated with beneficial changes in gut microbiota.
Takeaway
This study shows that a medicine called tofacitinib can help people with joint pain and also change the tiny living things in their tummy to be healthier.
Methodology
A case series of seven bio-naïve psoriatic arthritis patients treated with tofacitinib for 12 months, with assessments using clinical scores, laboratory tests, and gut microbiota analysis.
Limitations
The small sample size and monocentric nature limit the generalizability of the results.
Participant Demographics
{"age":"52.00 (33.00–56.00)","gender":"57.14% female","comorbidities":"57.14% with comorbidities","smoking":"28.57% smokers","disease_duration":"10.34 (0.4–13) years"}
Statistical Information
P-Value
p = 0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website